JP6152387B2 - Ｉ型およびｉｉ型糖尿病の処置 - Google Patents

Ｉ型およびｉｉ型糖尿病の処置 Download PDF

Info

Publication number
JP6152387B2
JP6152387B2 JP2014547360A JP2014547360A JP6152387B2 JP 6152387 B2 JP6152387 B2 JP 6152387B2 JP 2014547360 A JP2014547360 A JP 2014547360A JP 2014547360 A JP2014547360 A JP 2014547360A JP 6152387 B2 JP6152387 B2 JP 6152387B2
Authority
JP
Japan
Prior art keywords
insulin
compound
compounds
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014547360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513310A (ja
JP2015513310A5 (OSRAM
Inventor
アンドルー・ジー・リューム
マイケル・エス・サポリト
アレクサンダー・アール・オフマン
Original Assignee
メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド filed Critical メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド
Publication of JP2015513310A publication Critical patent/JP2015513310A/ja
Publication of JP2015513310A5 publication Critical patent/JP2015513310A5/ja
Application granted granted Critical
Publication of JP6152387B2 publication Critical patent/JP6152387B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014547360A 2011-12-12 2012-12-12 Ｉ型およびｉｉ型糖尿病の処置 Active JP6152387B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569496P 2011-12-12 2011-12-12
US61/569,496 2011-12-12
PCT/US2012/069072 WO2013090319A2 (en) 2011-12-12 2012-12-12 Treatment of type i and type ii diabetes

Publications (3)

Publication Number Publication Date
JP2015513310A JP2015513310A (ja) 2015-05-07
JP2015513310A5 JP2015513310A5 (OSRAM) 2016-01-28
JP6152387B2 true JP6152387B2 (ja) 2017-06-21

Family

ID=48613352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547360A Active JP6152387B2 (ja) 2011-12-12 2012-12-12 Ｉ型およびｉｉ型糖尿病の処置

Country Status (14)

Country Link
US (2) US20150190396A1 (OSRAM)
EP (1) EP2790704B1 (OSRAM)
JP (1) JP6152387B2 (OSRAM)
KR (1) KR102069395B1 (OSRAM)
CN (2) CN104271140B (OSRAM)
AU (2) AU2012352480A1 (OSRAM)
BR (1) BR112014014289A8 (OSRAM)
CA (1) CA2859156C (OSRAM)
IL (1) IL233004B (OSRAM)
MX (1) MX359171B (OSRAM)
RU (1) RU2646475C2 (OSRAM)
SG (2) SG11201403207WA (OSRAM)
WO (1) WO2013090319A2 (OSRAM)
ZA (1) ZA201404738B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10863264B2 (en) 2017-01-23 2020-12-08 David Sampson Vibration inducing tactile apparatus
JP7033662B2 (ja) * 2018-01-11 2022-03-10 バクワン ファーマスティカル カンパニー リミテッド 大規模なトリミドンの調製方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
EP1924262B1 (en) * 2005-08-22 2011-11-16 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
RU2316339C1 (ru) * 2006-09-13 2008-02-10 Общество С Ограниченной Ответственностью "Концерн О3" Способ получения препарата инсулина для перорального применения
JP2010518860A (ja) * 2007-02-20 2010-06-03 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性化剤の同定方法
CA2693809A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating irs-1 and akt
ES2530223T3 (es) * 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
US20130158055A1 (en) * 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
AU2018250795B2 (en) * 2017-04-10 2022-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of adipocytes

Also Published As

Publication number Publication date
RU2014128528A (ru) 2016-02-10
EP2790704A4 (en) 2015-09-02
RU2646475C2 (ru) 2018-03-05
SG10201604828QA (en) 2016-07-28
KR102069395B1 (ko) 2020-01-22
SG11201403207WA (en) 2014-09-26
KR20140107416A (ko) 2014-09-04
BR112014014289A2 (pt) 2017-06-13
CN104271140B (zh) 2016-11-23
AU2012352480A1 (en) 2014-07-17
IL233004B (en) 2020-01-30
WO2013090319A3 (en) 2014-12-04
JP2015513310A (ja) 2015-05-07
CN107007608A (zh) 2017-08-04
CA2859156A1 (en) 2013-06-20
EP2790704A2 (en) 2014-10-22
AU2017204652A1 (en) 2017-07-27
CN107007608B (zh) 2021-04-23
CA2859156C (en) 2020-10-06
IL233004A0 (en) 2014-07-31
HK1202819A1 (en) 2015-10-09
ZA201404738B (en) 2016-10-26
NZ626495A (en) 2016-03-31
CN104271140A (zh) 2015-01-07
EP2790704B1 (en) 2019-04-03
BR112014014289A8 (pt) 2017-06-13
US20200215068A1 (en) 2020-07-09
MX359171B (es) 2018-09-18
AU2017204652B2 (en) 2018-08-16
US20150190396A1 (en) 2015-07-09
MX2014006990A (es) 2015-02-05
WO2013090319A2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
US12064432B2 (en) Treatment of adipocytes
US20200215068A1 (en) Treatment of type i and type ii diabetes
WO2022026645A1 (en) Treatment of acute respiratory distress syndrome (ards)
US20210106581A1 (en) Treatment Of Liver Diseases
Reaume et al. Treatment of adipocytes
HK1202819B (en) Treatment of type i diabetes
NZ626495B2 (en) Treatment of type i and type ii diabetes
BR112019021140B1 (pt) Composição, e, uso de um ativador de lyn cinase e de um agonista de trpm8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170529

R150 Certificate of patent or registration of utility model

Ref document number: 6152387

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250